Piperidine 2,6-dione derivatives binding cereblon for protein degradation
Summary
EPO published patent application EP4065571A1 for Captor Therapeutics S.A. covering piperidine-2,6-dione derivatives designed to bind cereblon for targeted protein degradation. The application covers molecular glue degrader compounds with therapeutic applications in oncology (A61P 35/00) and inflammatory conditions, classified under multiple C07D heterocyclic chemistry subclasses. The publication establishes priority dates and creates prior art for competing entities developing related cereblon-modulating therapeutics.
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 31 changes logged to date.
What changed
EPO published patent application EP4065571A1 for piperidine-2,6-dione derivatives as cereblon-binding molecular glue degraders for targeted protein degradation, an emerging therapeutic modality with applications in oncology and inflammatory conditions. The publication covers 19 IPC classifications spanning heterocyclic chemistry (C07D subclasses) and pharmaceutical compositions (A61K, A61P), designating all major European patent jurisdictions. The publication establishes priority dates and creates prior art for competing compounds in the cereblon modulator chemical space.
Pharmaceutical and biotechnology companies developing molecular glue degraders, cereblon modulators, or related targeted protein degradation programs should review the published claims for potential overlap with their own compounds and assess freedom-to-operate implications. The patent publication may inform competitive landscape analyses for protein degradation therapeutics.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF
Publication EP4065571A1 Kind: A1 Apr 15, 2026
Applicants
Captor Therapeutics S.A.
Inventors
KACZANOWSKA, Katarzyna, COTTENS, Sylvain, PLUTA, Roman, DICKINSON, Niall, WALCZAK, Michal
IPC Classifications
C07D 401/12 20060101AFI20210604BHEP C07D 471/04 20060101ALI20210604BHEP A61K 31/454 20060101ALI20210604BHEP A61P 35/00 20060101ALI20210604BHEP C07D 403/12 20060101ALI20210604BHEP C07D 405/12 20060101ALI20210604BHEP C07D 405/14 20060101ALI20210604BHEP C07D 409/12 20060101ALI20210604BHEP C07D 409/14 20060101ALI20210604BHEP C07D 413/12 20060101ALI20210604BHEP C07D 417/12 20060101ALI20210604BHEP C07D 495/04 20060101ALI20210604BHEP C07D 495/14 20060101ALI20210604BHEP C07D 513/04 20060101ALI20210604BHEP A61K 31/55 20060101ALI20210604BHEP A61P 11/00 20060101ALI20210604BHEP A61P 17/00 20060101ALI20210604BHEP A61K 31/437 20060101ALI20210604BHEP A61K 31/4525 20060101ALI20210604BHEP A61K 31/4535 20060101ALI20210604BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.